Lasmiditan

Introduction Overview

Generic Name

lasmiditan

Brand Name

Reyvow

Dosage Form

oral tablet

Drug Class

Antimigraine agents

Pharmacokinetics

Absorption:
Lasmiditan, the active component of Reyvow, is rapidly absorbed following oral administration, achieving peak plasma concentrations within approximately 1.5 to 2 hours post-dose. The absorption profile indicates good bioavailability allowing effective systemic exposure. Food intake does not significantly affect lasmiditan's pharmacokinetic parameters, so it can be taken with or without food, providing flexibility and convenience in clinical use. The rate of absorption supports its use as an acute treatment for migraine by enabling swift onset of therapeutic action.

Distribution:
Lasmiditan exhibits a moderate volume of distribution, indicating distribution beyond the vascular compartment into tissues, including the central nervous system (CNS). It is lipophilic enough to cross the blood-brain barrier, consistent with its mechanism targeting central 5-HT(1F) receptors. Plasma protein binding is moderate, reducing potential significant displacement interactions. The ability to penetrate CNS tissues effectively ensures that lasmiditan can exert its antimigraine effect at neuronal sites implicated in migraine pathophysiology.

Metabolism:
Lasmiditan undergoes extensive hepatic metabolism primarily by secondary and tertiary amine oxidation, although the precise cytochrome P450 isoenzymes involved remain not fully elucidated. Metabolites formed are largely inactive regarding antimigraine activity. The metabolic pathway is considered non-inducing and non-inhibitory of major CYP enzymes, which lowers the risk of significant drug-drug interactions through metabolic pathways. Hepatic impairment may alter metabolism; however, clinical studies recommend caution and possible dose adjustment in significant liver dysfunction.

Elimination:
The elimination of lasmiditan and its metabolites occurs predominantly via renal excretion, with both parent drug and metabolites recovered in urine. The elimination half-life ranges approximately from 5 to 6 hours, supporting its use as a single-dose acute treatment. There is minimal accumulation with repeated dosing, though Reyvow is indicated for single-dose use per migraine episode. Renal impairment may modify elimination and necessitate clinical monitoring. Overall, the pharmacokinetic profile supports a predictable dosing regimen with a low incline for accumulation or prolonged systemic exposure.

Dosage Forms

Available Dosage Forms:
Reyvow is commercially available exclusively as an oral tablet intended for acute migraine treatment. Specific tablet strengths include:
- 50 mg
- 100 mg
- 200 mg

Dosages for Adults and Adolescents:
The recommended initial dose for adults is either 50 mg, 100 mg, or 200 mg taken orally once at the onset of a migraine attack. Only one dose should be taken in a 24-hour period. A second dose for the same migraine episode is not indicated as efficacy for repeat dosing within 24 hours has not been established. The dosing selection is guided by clinical judgment considering efficacy and tolerability. In clinical trials, doses up to 200 mg have been studied and found effective; however, patients initiating therapy may start at lower doses to gauge response.

Specific Patient Populations:
- Pediatric Use: Reyvow is not approved for use in pediatric populations under 18 years due to a lack of established safety and efficacy.
- Geriatric Use: No specific dosage adjustments are clearly delineated, but caution is advised considering potential comorbidities.
- Hepatic Impairment: Dose adjustment may be necessary due to altered metabolism and clearance, with close monitoring recommended.
- Renal Impairment: Limited data available; caution is advised because renal elimination predominates.

Clinical guidelines emphasize that Reyvow treats acute migraine attacks and is not indicated for migraine prophylaxis. Patients must avoid driving or hazardous activities for at least 8 hours post-dose because of associated CNS effects. Avoidance of multiple doses in 24 hours is critical to prevent adverse effects and lack of additional benefit.

Mechanism Of Action

Lasmiditan acts as a highly selective agonist for the serotonin 5-HT1F receptor subtype, distinguishing it from triptan class antimigraine agents which target 5-HT1B/1D receptors. Unlike triptans, lasmiditan's mechanism avoids vasoconstriction, making it safer for patients with cardiovascular risk factors.

At the molecular level, lasmiditan binds with high affinity to presynaptic 5-HT1F receptors located on trigeminal nerve endings. Activation of these G-protein-coupled receptors inhibits adenylate cyclase activity, leading to a reduction in cyclic AMP levels and subsequent modulation of ion channels. This decreases the release of proinflammatory neuropeptides and neurotransmitters such as calcitonin gene-related peptide (CGRP), substance P, and glutamate involved in nociceptive signaling pathways.

Cellularly, lasmiditan attenuates the activation and sensitization of trigeminovascular pathways that are central to the initiation and propagation of migraine pain. By reducing neuronal excitability and neurogenic inflammation within the trigeminal system and central pain processing centers in the brainstem, it interrupts the cascade responsible for migraine headache.

Clinically, lasmiditan's selective 5-HT1F receptor agonism provides effective acute migraine relief with a favorable cardiovascular safety profile compared to vasoconstrictive agents. Clinical trial evidence supports its efficacy in reducing pain and migraine-related symptoms such as photophobia and phonophobia. Moreover, lasmiditan's unique mechanism offers therapeutic options for patients contraindicated for triptans. Ongoing research continues to evaluate its impact on migraine pathophysiology and potential expanded clinical applications.

Pharmacological Actions

Selective agonism of serotonin 5-HT1F receptors
Inhibition of neuropeptide release (e.g., CGRP, substance P) from trigeminal neurons
Modulation of neuronal excitability via decreased cAMP signaling
Reduction of neurogenic inflammation within migraine pathways
Non-vasoconstrictive antimigraine effect differentiating it from triptans
Acute alleviation of migraine headache symptoms with or without aura
Central nervous system penetration allowing direct action on brainstem structures
Reduction in migraine-related associated symptoms such as nausea, photophobia, and phonophobia
Potential attenuation of peripheral and central sensitization mechanisms in migraine
Minimal interaction with other serotonin receptor subtypes reducing off-target effects
Low propensity for cardiovascular adverse events owing to receptor selectivity
Rapid onset of action facilitating effective treatment during migraine attacks
Single-dose efficacy with limited accumulation and short duration of systemic exposure
Controlled substance scheduling reflecting potential for CNS-related adverse effects

Therapeutic Or Clinical Uses

Acute treatment of migraine headaches with aura
Acute treatment of migraine headaches without aura
Treatment option for patients contraindicated for vasoconstrictive migraine agents
Management of migraine in adult patients requiring rapid symptom relief
Alternative therapy for patients with cardiovascular disease or risk factors
Use in patients with intolerance or inadequate response to triptans
Mitigation of migraine-associated symptoms such as nausea and sensitivity to light and sound
Reduction in the frequency of moderate to severe migraine attacks through effective acute intervention
Treatment in outpatient settings for self-administered migraine care
Supportive role in comprehensive migraine management plans
Acute relief intended only; not indicated for migraine prophylaxis
Use in patients requiring flexibility to dose with or without food
Suitable for patients where non-vasoconstrictive therapy is preferred
Regulated use due to controlled substance status for safe prescribing practices
Recommended for limited dosing frequency to minimize adverse effects and abuse potential

Side Or Adverse Effects

Dizziness, commonly reported and dose-related
Drowsiness or somnolence impacting patient alertness
Fatigue or general feeling of tiredness following administration
Paresthesia manifested as numbness or tingling sensations
Potential for serotonin syndrome when combined with serotonergic drugs
Transient increase in heart rate or palpitations
Nausea and gastrointestinal upset in some patients
Possible hypersensitivity reactions including urticaria and swelling
Impaired coordination or motor skills leading to increased risk during activities
Cognitive disturbances such as confusion or difficulty concentrating
Central nervous system depression effects intensified with concomitant sedatives
Rare but serious allergic reactions requiring emergency intervention
Risk of abuse or dependence due to controlled substance classification
Adverse events prompting patients to avoid driving or operating machinery post-dose
Headache exacerbation if overused beyond recommended dosing frequency

Precautions

Avoid taking more than one dose within a 24-hour period to reduce risk of adverse effects and lack of additional benefit
Do not drive or operate hazardous machinery for at least 8 hours after dosing due to CNS effects
Use with caution in patients with liver impairment due to altered metabolism and clearance
Assess patient history for drug addiction before prescribing as lasmiditan has abuse potential
Inform healthcare providers about all concomitant medications to prevent serotonin syndrome
Avoid concurrent use with other central nervous system depressants or sedatives unless supervised
Monitor blood pressure and cardiac status in patients with underlying cardiovascular disease
Pregnancy use only if benefits outweigh potential risks; enroll in pregnancy registry when applicable
Avoid alcohol consumption during treatment due to enhanced drowsiness and side effects
Exercise caution in elderly patients who may be more sensitive to CNS depressant effects
Advise patients on recognizing signs of serotonin syndrome and prompt medical evaluation
Do not share medication with others; storing securely to prevent misuse is essential
Evaluate potential drug interactions with herbal supplements and over-the-counter products
Use cautiously in patients with slow heartbeats or conduction abnormalities
Consider alternative migraine therapies if uncontrolled hypertension is present

Warnings

Reyvow is a Schedule V controlled substance due to potential for abuse, addiction, and dependence
Selling or distributing this medication is illegal and dangerous
Risk of serious impairment of mental alertness; refrain from driving or hazardous activities for at least 8 hours post-dose
Do not exceed the recommended single daily dose of 200 mg
Use is contraindicated in patients with known hypersensitivity to lasmiditan
Potential for serotonin syndrome when combined with serotonergic agents including antidepressants and herbal products
Overuse of migraine medications can lead to medication overuse headache or rebound headache phenomena
Safety for long-term or frequent use above four migraine attacks per month has not been established
Risk of accidental overdose especially if patient self-medicates improperly
May cause dizziness and somnolence affecting patient safety in routine activities
Pregnant or breastfeeding women should only use under strict medical supervision
Monitor for allergic reactions and discontinue if severe hypersensitivity occurs
Patients with history of substance use disorder require close monitoring
Potential interaction with drugs causing CNS depression
Store medication securely out of reach of children and unauthorized persons

Contraindication

Known allergy or hypersensitivity to lasmiditan or any tablet excipients
Use in pediatric patients under 18 years has not been established and is not recommended
Patients who have exhibited hypersensitivity reactions to other selective serotonin receptor agonists
Concurrent use with monoamine oxidase inhibitors (MAOIs) due to enhanced risk of serotonin syndrome
Use with caution or avoid in patients with severe hepatic impairment due to altered pharmacokinetics
Patients with a history of substance abuse without appropriate monitoring
Contraindicated in situations where single daily dosing cannot be ensured to prevent overdose
Individuals unable to abstain from activities requiring mental alertness for 8 hours post-dose
Known or suspected pregnancy only if benefit outweighs risk and under medical supervision
Severe renal impairment requiring individualized assessment and caution
Use with other serotonergic drugs without adequate washout period
Patients with documented severe cardiac conduction abnormalities without cardiology evaluation
Patients allergic to related antimigraine agents with cross-reactivity potential
Patients with uncontrolled hypertension or unstable cardiovascular disease
Situations where compliance with regulatory prescribing and storage requirements cannot be maintained

Drug Interactions

Concomitant use with other serotonergic agents such as SSRIs, SNRIs, and triptans increases risk of serotonin syndrome
Additive central nervous system depressant effects with opioids, benzodiazepines, muscle relaxants, and sedatives
Interaction with stimulant medications may exacerbate cardiovascular side effects
Potential reduced efficacy or enhanced adverse events when combined with alcohol
Possible pharmacodynamic interactions with herbal supplements like St. John's Wort affecting serotonin levels
No significant metabolic drug interactions via cytochrome P450 pathways reported, minimizing enzymatic interference
Careful monitoring advised when co-administered with migraine preventive agents to avoid overtreatment
Interaction potential with pharmacotherapies used for depression, anxiety, or Parkinson's disease
Concomitant use with antiemetics like metoclopramide may potentiate CNS adverse effects
Potential pharmacokinetic and pharmacodynamic interaction with other central nervous system active drugs
Concurrent administration with MAO inhibitors is contraindicated due to severe adverse effect risk
Other prescription and over-the-counter medications, vitamins, and supplements should be reviewed for possible interaction
Avoid or closely monitor combination with other controlled substances due to enhanced sedation
Patients should inform healthcare providers of all current drugs to tailor safe therapy
Use of drug interaction checkers is recommended prior to initiation to identify unknown interactions

Preparations Of The Drug

Oral tablet formulations available in 50 mg, 100 mg, and 200 mg strengths
Packaged in blister packs or bottles with child-resistant closures to prevent accidental ingestion
Stored at room temperature, protected from moisture and excessive heat to maintain stability
Supplied in prescription quantities only due to controlled substance classification
Packaging includes patient information leaflets detailing usage, precautions, and side effects
Available through pharmacy dispensing under strict regulatory controls to prevent diversion
No injectable or alternative formulations currently available for lasmiditan
Packaging designed to encourage adherence and proper dosing with clear labeling
Manufactured under sterile pharmaceutical standards ensuring drug purity and consistency
Included in REMS (Risk Evaluation and Mitigation Strategy) programs to monitor safe use
Distributed in dosage units suitable for single administration per migraine episode
Not combined with other active pharmaceutical ingredients; single-agent formulation only
Available from authorized drug wholesalers and pharmacies licensed for controlled substances
Storage and handling instructions emphasize securing medication from unauthorized access
Patient education materials often included to support correct and safe medication use